Perspective Therapeutics, Inc. has celebrating the first shipment and patient dosing from its second manufacturing facility for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals.

SunHydrogen, Inc. has announced the appointment of David Raney to the SunHydrogen Board of Directors.

SunHydrogen has joined the Texas Hydrogen Alliance, a coalition of industry leaders dedicated to advancing the hydrogen economy in Texas.

Integrated DNA Technologies has announced the expansion of its Archer™ next generation sequencing (NGS) assay solutions portfolio with the new Archer VARIANTPlex™ Lymphoma panel.

NanoMedtrix, LLC (NMTx) has recently won multiple patents related to the engineering of nanoparticles.

Perspective Therapeutics has announced that the U.S. Food and Drug Administration granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or "MC1R," is a protein that can be overexpressed in metastatic melanoma.